1. Home
  2. IMNN vs VNRX Comparison

IMNN vs VNRX Comparison

Compare IMNN & VNRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Imunon Inc.

IMNN

Imunon Inc.

N/A

Current Price

$1.00

Market Cap

7.9M

Sector

Health Care

ML Signal

N/A

Logo VolitionRX Limited

VNRX

VolitionRX Limited

N/A

Current Price

$0.20

Market Cap

7.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IMNN
VNRX
Founded
1982
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.9M
7.2M
IPO Year
2000
2012

Fundamental Metrics

Financial Performance
Metric
IMNN
VNRX
Price
$1.00
$0.20
Analyst Decision
Strong Buy
Buy
Analyst Count
4
5
Target Price
★ $17.00
$13.62
AVG Volume (30 Days)
95.7K
★ 1.3M
Earning Date
11-12-2026
11-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 38.00
EPS
★ N/A
N/A
Revenue
N/A
★ $1,727,384.00
Revenue This Year
N/A
$57.67
Revenue Next Year
N/A
$240.52
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ 40.04
52 Week Low
$0.81
$0.13
52 Week High
$4.60
$3.26

Technical Indicators

Market Signals
Indicator
IMNN
VNRX
Relative Strength Index (RSI) 36.60 38.57
Support Level N/A $0.15
Resistance Level $1.28 $0.72
Average True Range (ATR) 0.08 0.02
MACD -0.01 0.01
Stochastic Oscillator 23.08 74.51

Price Performance

Historical Comparison
IMNN
VNRX

About IMNN Imunon Inc.

Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective and durable responses across a broad array of human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit an immunological response. The company's clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer.

About VNRX VolitionRX Limited

VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on diagnostics and monitoring.

Share on Social Networks: